Related Experiment Video
Updated: Jul 1, 2025

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
Published on: January 28, 2021
Apolipoprotein A1 and high-density lipoprotein limit low-density lipoprotein transcytosis by binding SR-B1
Karen Y Y Fung1, Tse Wing Winnie Ho2, Zizhen Xu3
1Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada; Keenan Research Centre, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada.
Insights
High-density lipoprotein (HDL) may protect against atherosclerosis by competing with low-density lipoprotein (LDL) for binding to scavenger receptor B1 (SR-B1), thus reducing LDL deposition in arteries.
Area of Science:
- Cardiovascular Biology
- Lipid Metabolism
- Atherosclerosis Research
Background:
- Atherosclerosis involves low-density lipoprotein (LDL) deposition and oxidation in arteries, leading to occlusion.
- Transcytosis of LDL across endothelial cells is a key step in atherosclerosis development.
- High-density lipoprotein (HDL) is believed to offer protection against atherosclerosis.
Purpose of the Study:
- To investigate whether apolipoprotein A1 (APOA1), a component of HDL, can compete with LDL for scavenger receptor B1 (SR-B1) binding.
- To determine if HDL or APOA1 can inhibit LDL transcytosis and subsequent deposition in the arterial wall.
Main Methods:
- In vitro studies using coronary endothelial cells to quantify fluorescent LDL internalization and transcytosis.
- Microscale thermophoresis and affinity capture assays to assess interactions between SR-B1 and APOA1.
- In vivo experiments in male mice to evaluate the effect of increased HDL or APOA1 levels on LDL deposition.
Main Results:
- SR-B1 and APOA1 were found to interact, with enhanced binding observed for the APOA1-Milano variant.
- Increased HDL levels in mice reduced the acute deposition of fluorescent LDL in the aorta.
- Both wild-type APOA1 and APOA1-Milano inhibited LDL deposition, with APOA1-Milano showing a more potent effect.
Conclusions:
- HDL, through APOA1, may limit LDL transcytosis by competing for SR-B1 binding.
- This competition potentially reduces LDL deposition in the sub-arterial space, contributing to HDL's atheroprotective role.
- APOA1-Milano demonstrates a stronger inhibitory effect on LDL deposition compared to wild-type APOA1.
Abstract:
Atherosclerosis results from the deposition and oxidation of LDL and immune cell infiltration in the sub-arterial space leading to arterial occlusion. Studies have shown that transcytosis transports circulating LDL across endothelial cells lining blood vessels. LDL transcytosis is initiated by binding to either scavenger receptor B1 (SR-B1) or activin A receptor-like kinase 1 on the apical side of endothelial cells leading to its transit and release on the basolateral side. HDL is thought to partly protect individuals from atherosclerosis due to its ability to remove excess cholesterol and act as an antioxidant. Apolipoprotein A1 (APOA1), an HDL constituent, can bind to SR-B1, raising the possibility that APOA1/HDL can compete with LDL for SR-B1 binding, thereby limiting LDL deposition in the sub-arterial space. To examine this possibility, we used in vitro approaches to quantify the internalization and transcytosis of fluorescent LDL in coronary endothelial cells. Using microscale thermophoresis and affinity capture, we find that SR-B1 and APOA1 interact and that binding is enhanced when using the cardioprotective variant of APOA1 termed Milano (APOA1-Milano). In male mice, transiently increasing the levels of HDL reduced the acute deposition of fluorescently labeled LDL in the atheroprone inner curvature of the aorta. Reduced LDL deposition was also observed when increasing circulating wild-type APOA1 or the APOA1-Milano variant, with a more robust inhibition from the APOA1-Milano. The results suggest that HDL may limit SR-B1-mediated LDL transcytosis and deposition, adding to the mechanisms by which it can act as an atheroprotective particle.
Related Concept Videos
Receptor-mediated Endocytosis
Drug Binding to Blood Components
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
Regulation of Nuclear Protein Sorting
Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
Factors Affecting Protein-Drug Binding: Protein-Related Factors
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
Drug Distribution: Plasma Protein Binding

